Table 2.
Number of patients responding | ||
---|---|---|
At baseline (%) | Following initiation of HAART (%) | |
Transient antigens | ||
PPD | 8 (22) | 17 (47) |
FLU | 7 (19) | 17 (47) |
Tetanus | 11 (31) | 15 (42) |
Persistent antigens | ||
HSV | 17 (47) | 27 (75) |
CMV | 10 (28)* | 21 (60)* |
Candida | 11 (31) | 24 (67) |
HIV-1 p24 | 2 (6) | 10 (27) |
HIV-1 gp120 | 2 (6) | 11 (31) |
HIV-1 nef | 2 (6) | 19 (7) |
Patient 1 was not assessed for CMV responses, thus the sample size for CMV was 35 patients.